Find a Trial

Trial Summary

Protocol No.CTO-20190135
Principal InvestigatorDurm, Greg
PhasePhase I/II
Age GroupAdult
TitleA Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
DescriptionTo evaluate the safety and tolerability of AMG 510 administered in investigational regimens in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Men or women greater than or equal to 18 years old.
  • Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12Cmutation identified through molecular testing.
  • Cannot have brain tumor as primary site of disease.
For a full list of participation criteria, please visit
Applicable Disease SitesAny Site
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632